Nontuberculous mycobacterial pulmonary disease and lung cancer: a retrospective case series Authors: Xuefen Chen, Chen Gong Published: 2026 ABSTRACT AbstractBackgroundThe incidence of nontuberculous mycobacterial pulmonary disease (NTM-PD) has increased worldwide. However, the clinical characteristics and optimal management of patients with concomitant lung cancer and NTM-PD remain poorly understood. This retrospective case series aimed to investigate the clinical characteristics, microbiological findings, treatment strategies, and clinical outcomes of patients with lung cancer complicated by NTM-PD.MethodsWe retrospectively reviewed the clinical data of 13 patients with concomitant lung cancer and NTM-PD at our institution between January 2020 and January 2025. Demographic characteristics, clinical manifestations, microbiological findings, tumor stage, histological subtype, driver gene alterations, treatment strategies, and clinical outcomes were collected and analyzed. NTM species were identified by metagenomic next-generation sequencing (mNGS).ResultsA total of 13 patients (8 men and 5 women) were included, with a median age of 64 years (interquartile range, 59.5–71.0 years). Adenocarcinoma was the most common histological subtype (n=7). The predominant NTM species were Mycobacterium abscessus (n=4) and the Mycobacterium avium complex (MAC) (n=5). Eleven patients received anti-NTM therapy, whereas two were managed conservatively because their respiratory symptoms improved after anticancer treatment and their pulmonary lesions remained radiologically stable. Individualized treatment sequencing enabled most patients to complete anticancer therapy. Two patients with stage I disease underwent delayed surgery following short-term anti-NTM treatment. At the last follow-up, three patients had died and ten remained alive. The mean follow-up duration was 18.69 months (range, 6–53 months).ConclusionsAmong patients with lung cancer complicated by NTM infection, the predominant species were MAC and Mycobacterium abscessus. No obvious worsening of NTM-PD was observed during concurrent treatment, but NTM infection may delay the timing of surgery for early-stage lung cancer.Keywords: Lung cancer, nontuberculous mycobacterial pulmonary disease (NTM-PD), metagenomic next-generation sequencing (mNGS), Mycobacterium abscessus, multidisciplinary management, case series Highlight box Key findings • In this retrospective case series of 13 patients with concomitant lung cancer and pulmonary nontuberculous mycobacterial disease (NTM-PD), Mycobacterium avium complex and Mycobacterium abscessus were the predominant pathogens. Eleven patients received anti-NTM therapy, and no obvious worsening of NTM-PD was observed during concurrent anticancer treatment. Two patients with early-stage lung cancer underwent surgery after short-term anti-NTM treatment. What is known and what is new? • The coexistence of lung cancer and NTM-PD creates diagnostic and therapeutic challenges because of overlapping radiological findings, species-specific antimicrobial requirements, treatment toxicity, and potential drug-drug interactions. • This study provides case-level real-world information on microbiological species, treatment sequencing, and clinical outcomes, and highlights the treatment complexity encountered in patients with M. abscessus infection. What is the implication, and what should change now? • Management should be individualized according to NTM species, infection activity, tumor stage, treatment urgency, and drug tolerability. Larger multicenter studies are required before standardized treatment sequencing can be recommended. Introduction Nontuberculous mycobacteria (NTM) are mycobacteria other than the Mycobacterium tuberculosis complex and Mycobacterium leprae, comprising more than 190 species and subspecies (1). In recent years, the prevalence of nontuberculous mycobacterial disease has increased annually (2), and lung cancer is one of the most common cancers worldwide and a leading cause of cancer-related death (3). With population aging, the widespread use of imaging examinations, particularly high-resolution computed tomography (CT), and improved clinician awareness of both diseases, the detection rate of comorbid NTM lung disease and lung cancer has gradually increased, and the potential association between the two has received growing attention. A recent systematic review by Kashizaki et al. summarized 92 cases of concurrent lung cancer and NTM pulmonary disease (NTM-PD), reporting a median age of 69 years, Mycobacterium avium as the most common pathogen (80.5%), and adenocarcinoma as the predominant histology. Spatial analysis showed that over half of the cases coexisted within the same lesion or the same lobe. However, given the limited number of reported cases, the clinical features and optimal management of this co-occurrence remain poorly defined, warranting further investigation (4). NTM-PD and lung cancer may interact through multiple mechanisms. On the one hand, chronic NTM infection has been suggested to be associated with the development of lung cancer, although the underlying mechanisms remain incompletely understood (5). On the other hand, in patients with lung cancer, tumor-related wasting, suppression of immune function, or antitumor treatments such as chemoradiation, targeted therapy, and immunotherapy can reduce local or systemic immunity, thereby increasing the risk of susceptibility to NTM or reactivation of latent infection. In addition, NTM-PD may present as pulmonary nodules, masses, or mass-like consolidation that can mimic lung cancer, potentially leading to diagnostic difficulty or unnecessary invasive procedures (6). However, clinical studies on NTM-PD complicated by lung cancer remain limited, consisting mostly of case reports or small case series, and systematic analyses of clinical characteristics, treatment strategies, and prognosis are lacking (7). When the two diseases coexist, clinicians face numerous challenges because of atypical clinical manifestations, diagnostic difficulty, interactions between anti-NTM drugs and antineoplastic agents, and overlapping toxicities. This study aimed not only to describe the clinical characteristics and microbiological spectrum of patients with concomitant lung cancer and NTM-PD, but also to summarize real-world diagnostic and therapeutic strategies adopted in different clinical scenarios, thereby providing practical information for multidisciplinary management. We present this article in accordance with the AME Case Series reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1508/rc). Methods Study design and patients This retrospective single-center case series included 13 consecutive patients with concomitant lung cancer and nontuberculous mycobacterial pulmonary disease (NTM-PD) who were treated at The First Affiliated Hospital of Guangxi Medical University between January 2020 and January 2025. All patients had histopathologically confirmed lung cancer and were evaluated for suspected pulmonary infection during routine clinical care. Clinical information was retrospectively retrieved from electronic medical records. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University (Approval No. 2026-E0459), and the requirement for informed consent was waived because of the retrospective nature of the study. Written informed consent was obtained from the patients for publication of this article and the accompanying images. Patients were included if they met all of the following criteria: age ≥18 years; histopathologically confirmed primary lung cancer; pulmonary NTM disease diagnosed during the diagnostic evaluation or treatment of lung cancer based on an integrated assessment of compatible clinical manifestations, characteristic chest CT findings, microbiological evidence [bronchoalveolar lavage fluid (BALF) or lung tissue metagenomic next-generation sequencing (mNGS)], and multidisciplinary clinical judgment after exclusion of pulmonary tuberculosis; complete demographic, laboratory, imaging, treatment, and follow-up data were available. Patients were excluded if they met any of the following criteria: active pulmonary tuberculosis; isolated NTM detection without compatible clinical or radiological evidence suggestive of active pulmonary NTM disease; incomplete medical records or missing key clinical data. Clinical, radiological, microbiological, treatment, and follow-up data were retrospectively collected from the electronic medical records. Data collection Demographic characteristics, smoking history, respiratory symptoms (including cough, sputum production, fever, and hemoptysis), nutritional risk, comorbidities, laboratory findings (including routine blood tests, serum albumin, and carcinoembryonic antigen), imaging findings, microbiological results, pathological findings, antitumor treatment, anti-NTM treatment, and clinical outcomes were retrospectively collected. Follow-up information was obtained from inpatient records, outpatient visits, and telephone interviews. Follow-up duration was calculated from the date of diagnosis to the date of death or the last follow-up (August 30, 2025). Diagnostic criteria Lung cancer was diagnosed histopathologically according to the 2015 World Health Organization Classification of Lung Tumors (8). Tumor stage was determined according to the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system. Patients with suspected concomitant NTM-PD were evaluated according to the 2007 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) clinical practice guideline (9). The diagnosis was established based on a comprehensive assessment of clinical manifestations, chest CT findings, exclusion of pulmonary tuberculosis, and microbiological evidence. Microbiological evaluation All patients underwent sputum or BALF smears for acid-fast bacilli (AFB), and all smear results were negative. NTM species were identified by mNGS, using BALF specimens in 12 patients and lung tissue in one patient. Dedicated NTM culture and drug susceptibility testing were not available at our institution during the study period. Pathological evaluation Histopathological diagnosis of lung cancer was established using bronchoscopic biopsy, CT-guided percutaneous lung biopsy, pleural effusion cytology, or surgical specimens. Acid-fast staining of pathological specimens was performed in all patients and yielded negative results. Granulomatous inflammation was observed in one patient. Statistical analyses Owing to skewed distributions, continuous data were presented as medians with interquartile ranges (IQRs), and categorical variables were expressed as percentages. Statistical analyses and table generation were performed using SPSS software (version 22.0). Results Baseline characteristics Among the 13 patients, 8 (61.5%) were male and 5 (38.5%) were female. The median age at diagnosis was 64 years (IQR, 59.5–71.0 years). Five patients (38.5%) had a smoking history, whereas 8 (61.5%) had never smoked. All patients presented with respiratory symptoms, including cough and sputum production, while fever and hemoptysis were observed in 2 and 4 patients, respectively. Nutritional risk (NRS-2002 score ≥3) was identified in 4 patients. Comorbidities included previous pulmonary tuberculosis (n=1), chronic obstructive pulmonary disease (n=1), polymyositis with left breast cancer (n=1), and diabetes mellitus (n=1). Elevated carcinoembryonic antigen (CEA) levels were observed in 4 patients (30.8%), and anemia in 4 patients (30.8%). NTM-related CT findings were most commonly nodular lesions (6/13, 46.2%), and lung cancer and NTM lesions were located in the same lobe in 8 patients (61.5%). Representative CT images of Patients 5 and 8 are shown in Figure 1. Baseline demographic and clinical characteristics are summarized in Table 1. Chest CT findings in two patients with concomitant lung cancer and pulmonary nontuberculous mycobacterial disease. (A,B) Patient 5. Chest CT revealed an irregular soft tissue density shadow in the medial segment of the right lower lobe near the hilum, with unclear margins and a size of approximately 3.5 cm × 3.5 cm × 1.6 cm. Scattered patchy and nodular areas of increased density were observed in both lungs and the right lower lobe. Some of the lesions contained cavities. White arrows indicate the irregular right lower-lobe hilar lesion and representative bilateral patchy/nodular lesions, including cavitary lesions. (C-E) Patient 8. Chest CT revealed patchy, nodular, and cord-like dense shadows in multiple lobes of both lungs, with blurred margins. Large patchy dense shadows were observed in the middle and lower lobes of the right lung, with visible air-filled bronchi within the lesions. Black arrows indicate the large patchy dense opacities in the middle and lower lobes of the right lung. CT, computed tomography. Table 1Baseline demographic and clinical characteristics of the study population (n=13)CharacteristicValueAge, years64 (59.5–71.0)Sex Male8 Female5BMI, kg/m222.31 (19.03–23.27)Smoking status Ever smoker (current or former)5 Never smoker8Clinical manifestations Cough13 Sputum production13 Fever2 Hemoptysis4 Nutritional risk (NRS-2002 ≥3)4Comorbidities Hypertension4 Previous pulmonary tuberculosis1 Chronic obstructive pulmonary disease1 Diabetes mellitus1 Coronary artery disease2 Polymyositis1 Breast cancer1Laboratory findings Anemia (hemoglobin level <130 g/L in men and <115 g/L in women)4 Elevated CEA (>5.0 ng/mL)4Data are presented as median (interquartile range) or number of patients. BMI, body mass index; CEA, carcinoembryonic antigen; NRS-2002, Nutritional Risk Screening 2002. Baseline demographic and clinical characteristics of the study population (n=13) Data are presented as median (interquartile range) or number of patients. BMI, body mass index; CEA, carcinoembryonic antigen; NRS-2002, Nutritional Risk Screening 2002. Microbiological and diagnostic findings Sputum and BALF AFB smears were negative in all 13 patients. Mycobacterium tuberculosis infection was excluded based on negative AFB smears, negative Xpert results, and comprehensive clinical evaluation. Pathological acid-fast staining was negative in all 13 patients, while granulomatous inflammation was identified in one patient (P4). NTM infection was confirmed by mNGS of BALF in 12 patients and lung tissue in one patient. The identified NTM species included Mycobacterium abscessus (n=4), Mycobacterium intracellulare (n=3), Mycobacterium avium (n=1), Mycobacterium kansasii (n=1), Mycobacterium gordonae (n=1), Mycobacterium lentiflavum (n=1), Mycobacterium novocastrense (n=1), and one additional isolate identified only at the Mycobacterium avium complex (MAC) level (n=1). Thus, MAC accounted for 5 of the 13 cases. During the study period, mycobacterial culture for NTM was not routinely available at our institution. The interval between the two diagnoses was less than 1 month. Detailed microbiological characteristics, treatment regimens, and clinical outcomes are summarized in Table 2. Table 2Individual clinicopathological characteristics, diagnostic findings, treatment strategies, and outcomes of patients with concomitant lung cancer and nontuberculous mycobacterial pulmonary diseaseCaseHistologyAJCC stageDriver alterationNTM speciesDiagnostic evidenceAnti-NTM regimen†Anticancer treatmentOutcomeFollow-up (months)P1AdenocarcinomaIVEML4-ALK fusion M. intracellulare BALF mNGSNoneEnsartinib; switched to pemetrexed + nedaplatin + bevacizumab after disease progressionDead28P2AdenocarcinomaIVEGFR exon 19 deletionMACBALF mNGSCefoxitin + clarithromycin + rifampicin + ethambutolOsimertinib + intrapleural Endostar + bevacizumabAlive16P3Adenosquamous carcinomaIII– M. abscessus BALF mNGSLinezolid + ethambutol + rifampicin + intravenous amikacin; followed by azithromycin + linezolid + moxifloxacinSurgery, followed by nedaplatin + pemetrexed + adebrelimabAlive11P4Squamous cell carcinomaIII– M. avium BALF mNGSClarithromycin + rifampicin + ethambutolCarboplatin + nab-paclitaxelAlive16P5Squamous cell carcinomaIII– M. intracellulare BALF mNGSRifampicin + ethambutol + azithromycin + moxifloxacinCarboplatin + nab-paclitaxel + camrelizumab, followed by surgeryAlive13P6AdenocarcinomaIVEGFR exon 19 deletion M. intracellulare BALF mNGSIntravenous cefoxitin + moxifloxacin + rifampicin + ethambutol during hospitalization; followed by moxifloxacin + rifampicin + ethambutol after dischargeAfatinib Dead6P7Squamous cell carcinomaI– M. lentiflavum BALF mNGSMoxifloxacin + clarithromycin + linezolidSurgeryAlive13P8AdenocarcinomaIIIEGFR exon 19 deletion M. kansasii BALF mNGSIsoniazid + rifampicin + ethambutol + moxifloxacinIcotinibAlive53P9AdenocarcinomaI– M. novocastrense BALF mNGSNoneThoracoscopic left upper lobectomyAlive40P10Small-cell lung cancerIII– M. gordonae BALF mNGSRifampicin + ethambutol + azithromycin + moxifloxacinEtoposide + nedaplatinAlive15P11AdenocarcinomaI– M. abscessus BALF mNGSLinezolid + azithromycin + moxifloxacinSurgeryAlive9P12AdenocarcinomaI– M. abscessus BALF mNGSImipenem + tigecycline + clarithromycin + intravenous amikacin; subsequently modified because of drug intoleranceThoracoscopic left lower segmentectomyAlive16P13Squamous cell carcinomaII– M. abscessus Lung tissue mNGSMoxifloxacin + clarithromycinNoneDead7All patients had negative sputum and BALF acid-fast bacilli smears, negative tests for Mycobacterium tuberculosis, and negative pathological acid-fast staining. Granulomatous inflammation was identified in one patient (P4). Patient 1 died of respiratory failure caused by tumor progression, patient 6 died of brain herniation caused by tumor progression, and the cause of death for patient 13 was unknown. Tumor staging was based on the eighth edition of the AJCC TNM staging system. †, only the principal anti-NTM regimen is presented. Dose adjustments and regimen modifications during follow-up are not fully shown. AJCC, American Joint Committee on Cancer; BALF, bronchoalveolar lavage fluid; MAC, Mycobacterium avium complex; mNGS, metagenomic next-generation sequencing; NTM, nontuberculous mycobacterial. Individual clinicopathological characteristics, diagnostic findings, treatment strategies, and outcomes of patients with concomitant lung cancer and nontuberculous mycobacterial pulmonary disease All patients had negative sputum and BALF acid-fast bacilli smears, negative tests for Mycobacterium tuberculosis, and negative pathological acid-fast staining. Granulomatous inflammation was identified in one patient (P4). Patient 1 died of respiratory failure caused by tumor progression, patient 6 died of brain herniation caused by tumor progression, and the cause of death for patient 13 was unknown. Tumor staging was based on the eighth edition of the AJCC TNM staging system. †, only the principal anti-NTM regimen is presented. Dose adjustments and regimen modifications during follow-up are not fully shown. AJCC, American Joint Committee on Cancer; BALF, bronchoalveolar lavage fluid; MAC, Mycobacterium avium complex; mNGS, metagenomic next-generation sequencing; NTM, nontuberculous mycobacterial. Clinicopathological characteristics of lung cancer According to the eighth edition of the AJCC TNM staging system, four patients had stage I disease, one had stage II disease, five had stage III disease, and three had stage IV disease. Histological examination revealed seven adenocarcinomas, four squamous cell carcinomas, one adenosquamous carcinoma, and one small-cell lung cancer. Driver gene alterations were identified in four patients, including three with EGFR exon 19 deletion and one with an EML4-ALK fusion. Among the three patients with stage IV disease, metastatic sites included intrapulmonary metastasis in one patient, brain metastasis in one patient, and pleural metastasis in two patients; Patient 1 had both intrapulmonary and pleural metastases. Treatment and outcomes Among the 13 patients, 11 received anti-NTM therapy, whereas 2 were managed without anti-NTM treatment because their respiratory symptoms improved after anticancer therapy and their pulmonary lesions remained radiologically stable during follow-up. Among the 11 treated patients, five initiated anti-NTM therapy concurrently with anticancer treatment, three underwent surgery after approximately 1 month of anti-NTM therapy, one initiated anti-NTM therapy because of radiological progression of pulmonary lesions during anticancer treatment, one was diagnosed with NTM-PD within 1 month after surgery and subsequently received anti-NTM therapy, and one received anti-NTM therapy alone after declining anticancer treatment. Regarding anticancer treatment, one patient declined treatment, four underwent surgery alone, one underwent surgery followed by chemotherapy and immunotherapy, one received chemotherapy and immunotherapy followed by surgery, three received targeted therapy alone, two received chemotherapy alone, and one received chemotherapy combined with targeted therapy. As of the follow-up cutoff date (August 30, 2025), three patients had died and ten remained alive. The mean follow-up duration was 18.69 months (range, 6–53 months). No planned anticancer therapy was discontinued or permanently postponed because of anti-NTM drug toxicity or rifampicin-related interaction. Discussion This study retrospectively analyzed the clinical characteristics of 13 patients with NTM combined with lung cancer. We found that lung cancer with NTM infection occurred mainly in nonsmoking male patients with adenocarcinoma; MAC and Mycobacterium abscessus are the most common NTM species. No obvious worsening of NTM-PD was observed during concurrent treatment in this small retrospective series. The impact of NTM infection on the timing of surgery for early-stage lung cancer warrants attention. Pathophysiological and clinical interplay between NTM-PD and lung cancer The coexistence of lung cancer and pulmonary nontuberculous mycobacterial disease (NTM-PD) reflects a complex bidirectional interaction involving structural lung disease, immune dysregulation, and chronic inflammatory remodeling (10,11). Recent evidence suggests that chronic airway inflammation and bronchiectasis associated with NTM infection may contribute to carcinogenesis through sustained epithelial injury and aberrant immune activation (12). Conversely, malignancy-associated immune suppression and tumor-related airway obstruction may facilitate NTM colonization and infection, creating a self-reinforcing pathogenic cycle (13). Within this biological framework, the baseline characteristics of our study provide additional clinical support. Rather than being driven predominantly by traditional smoking-related risk, the population was characterized by a high proportion of never-smokers (61.5%) and a notable prevalence of nutritional risk (30.8%). These findings suggest that host susceptibility in lung cancer-associated NTM-PD may be more closely related to systemic frailty and impaired nutritional–immune status. Diagnostic complexity and species-level microbiological significance The diagnosis of pulmonary NTM disease in patients with lung cancer remains particularly challenging because radiological abnormalities caused by NTM infection frequently overlap with primary tumors, post-obstructive pneumonia, treatment-related inflammatory changes, and metastatic lesions, making differentiation based on imaging alone difficult (10). In our cohort, this diagnostic challenge was reflected by the observation that the pulmonary tumor and NTM lesions were located within the same lobe in 8 of the 13 patients, potentially increasing the difficulty of distinguishing infectious lesions from malignant progression during routine radiological evaluation. Another notable finding of this study is that all patients were diagnosed by mNGS of BALF or lung tissue. Although mycobacterial culture remains the microbiological gold standard recommended by current guidelines (10), our findings suggest that mNGS may provide valuable complementary microbiological information in selected patients with suspected NTM-PD who have negative conventional microbiological results or when rapid species identification is clinically required. Nevertheless, mNGS results should always be interpreted together with clinical manifestations and radiological findings, because detection of NTM DNA alone cannot reliably distinguish active disease from transient colonization or environmental contamination (10,11). Species-level identification has direct therapeutic implications because different NTM species exhibit distinct pathogenicity and antimicrobial susceptibility profiles (14). In our study, MAC and Mycobacterium abscessus complex (MABC) together accounted for 9 of the 13 cases (69.2%), consistent with previous epidemiological studies reporting these organisms as the predominant causes of pulmonary NTM disease in East Asia (11). However, despite their similar frequency, their clinical behavior differed substantially. Patients with MAC generally followed a relatively stable clinical course, whereas MABC infection was associated with more complicated management, including intensive multidrug therapy, frequent regimen modification because of drug intolerance, and postponement of surgery in selected early-stage patients. These observations are in accordance with previous reports demonstrating that MABC pulmonary disease is associated with poorer treatment outcomes and greater therapeutic complexity than MAC disease (15). Taken together, our findings emphasize that the value of microbiological diagnosis extends beyond confirmation of NTM infection. Early species-level identification may facilitate individualized therapeutic planning, particularly in patients with concomitant lung cancer, by helping clinicians anticipate treatment complexity, evaluate the urgency of anti-NTM therapy, and coordinate the timing of oncological intervention. Mycobacterium abscessus as a therapeutic bottleneck in lung cancer patients Mycobacterium abscessus represents the most clinically challenging pathogen in NTM-PD due to intrinsic resistance to multiple antimicrobial classes, including macrolides (via inducible erm genes), beta-lactams, and fluoroquinolones (14). Therapeutic regimens often require prolonged multidrug combinations including intravenous amikacin, imipenem, cefoxitin, and tigecycline, which are frequently limited by toxicity (10). Real-world studies have also reported high rates of treatment discontinuation or adjustment during MABC therapy, further highlighting its substantial therapeutic burden (16). Treatment sequencing: balancing oncologic urgency and infection control A central clinical challenge in this study was determining whether anti-NTM therapy should precede, follow, or occur concurrently with anticancer therapy. In early-stage lung cancer with active MABC infection (Patient 11), preoperative anti-NTM therapy was prioritized to reduce infectious burden before surgical resection. Previous studies have also examined the clinical impact of pulmonary NTM infection in patients undergoing lung cancer surgery (17). Conversely, in Patient 12, anti-NTM therapy was initiated after lung cancer surgery without delaying oncological management. This case illustrates that the timing of anti-NTM therapy may need to be individualized according to the relative clinical priority of the two diseases. Previous studies have also documented NTM-PD during long-term follow-up after lung cancer surgery (18). These observations reinforce that treatment sequencing should be individualized rather than protocol-driven, based on tumor stage, infection severity, and surgical feasibility. Real-world antimicrobial toxicity and individualized regimen adaptation in MABC In clinical practice, treatment of Mycobacterium abscessus pulmonary disease is frequently complicated by cumulative drug toxicity and poor tolerability (10,15). Although current guidelines recommend intensive regimens containing parenteral agents such as amikacin, imipenem/cilastatin, cefoxitin, or tigecycline during the initial phase, these recommendations are largely based on expert consensus and observational studies, and their implementation is often difficult in patients with concomitant malignancy who require simultaneous anticancer treatment (10). Our study illustrates this real-world dilemma. Patient 12 initially received an intensive regimen consisting of imipenem, tigecycline, clarithromycin, and intravenous amikacin, but treatment had to be modified because of poor tolerance to the intravenous agents. Nevertheless, multidrug therapy was maintained by adjusting the regimen according to the patient’s clinical condition, and no obvious progression of pulmonary NTM disease was observed during follow-up. Similarly, Patient 3 successfully completed perioperative anti-NTM therapy despite requiring sequential modification of antimicrobial agents. These cases suggest that, in patients with lung cancer, the primary goal may not always be strict adherence to a predefined regimen but rather maintenance of effective antimicrobial coverage while preserving the patient’s ability to continue potentially curative or life-prolonging oncological treatment. This concept is particularly relevant in patients with concomitant lung cancer because treatment tolerance directly influences the feasibility of multimodal therapy. In our study, despite individualized modification of anti-NTM regimens, no patient discontinued or permanently postponed planned anticancer therapy because of anti-NTM drug toxicity, and no obvious deterioration of NTM-PD attributable to anticancer treatment was observed. Although this observation should be interpreted cautiously given the small sample size, it suggests that flexible adjustment of anti-NTM therapy may represent a pragmatic strategy for balancing infection control with cancer treatment in carefully selected patients. Rather than interpreting regimen modification as evidence of inadequate treatment, we believe it should be regarded as an adaptive therapeutic strategy in real-world clinical practice. In patients with concomitant lung cancer and MABC pulmonary disease, individualized adjustment based on adverse events, treatment tolerance, and oncological priority may be more clinically meaningful than rigid adherence to standardized regimens. Future prospective studies are needed to determine whether this individualized approach can improve long-term microbiological and oncological outcomes while reducing treatment-related toxicity. Immunological and pharmacological interactions in dual disease management The coexistence of malignancy and chronic mycobacterial infection is characterized by complex bidirectional interactions involving both immune dysregulation and pharmacological constraints. Cancer-associated immune dysfunction may increase susceptibility to pulmonary NTM infection, particularly in patients with underlying structural lung disease (12). This immunological overlap may partially explain why NTM-PD frequently coexists with lung cancer in patients with underlying structural lung disease. At the pharmacological level, rifampicin is a well-known potent inducer of cytochrome P450 enzymes, with the potential to significantly reduce the plasma exposure of tyrosine kinase inhibitors and cytotoxic agents, thereby raising concerns regarding possible attenuation of anticancer efficacy (19). Theoretically, such interactions could necessitate modification or avoidance of rifampicin-containing regimens in patients receiving EGFR-TKIs or ALK inhibitors. However, an important finding in the present study is that rifampicin was used in several patients without requiring alteration of the planned anticancer treatment strategy. In these cases, anticancer therapy—including targeted therapy and chemotherapy—was maintained without dose adjustment or discontinuation attributable to anti-NTM treatment. This observation suggests that, in real-world clinical practice, pharmacokinetic interactions may not always translate into clinically significant treatment modifications, particularly when careful patient selection and multidisciplinary monitoring are applied. This discrepancy between theoretical interaction risk and observed clinical management may be explained by several factors. First, anticancer regimens were selected with consideration of potential drug–drug interactions, allowing compatible combinations in selected patients. Second, the duration and intensity of rifampicin exposure in NTM-PD treatment may vary, potentially limiting sustained pharmacokinetic impact in some clinical contexts. Third, close clinical monitoring may have allowed early detection and management of toxicity or disease progression without necessitating modification of oncological therapy. Taken together, these findings highlight that the presence of potential drug–drug interactions should not automatically preclude the concurrent use of rifampicin and anticancer agents. Instead, treatment decisions should be individualized based on cancer stage, molecular targets, expected therapeutic benefit, and infection severity. In carefully selected patients, concurrent management of NTM-PD and lung cancer may be feasible without compromising oncological treatment delivery. Multidisciplinary decision-making, clinical implications, and future directions Given the complexity of managing patients with concomitant lung cancer and NTM-PD, clinical decision-making should integrate oncological status, infection severity, and treatment tolerability, ideally through multidisciplinary collaboration. In this study, most patients were managed through individualized treatment planning, allowing either concurrent or sequential administration of anti-NTM and anticancer therapy according to clinical priorities. Importantly, this individualized approach did not result in obvious deterioration of NTM-PD in the majority of cases during follow-up, suggesting that carefully selected patients may tolerate dual-disease management under close clinical monitoring. Species-level identification may also inform treatment planning, particularly for difficult-to-treat species such as Mycobacterium abscessus. In real-world practice, treatment sequencing should take into account tumor stage, infection severity, treatment tolerability, potential drug-drug interactions, and the urgency of oncological treatment. In selected early-stage cases, active NTM-PD resulted in short-term postponement of surgery but did not preclude definitive oncological treatment. These observations highlight the complexity of determining the optimal timing and sequencing of treatment in patients with concomitant lung cancer and NTM-PD. The small sample size, retrospective single-center design, heterogeneous treatment strategies, and relatively short follow-up in some patients limit the conclusions that can be drawn from this case series. Larger multicenter studies with standardized microbiological assessment and longer follow-up are needed to clarify how NTM species, infection activity, and anticancer treatment influence treatment sequencing and clinical outcomes in patients with concomitant lung cancer and NTM-PD. Conclusions Lung cancer combined with NTM infection is a complex clinical issue that requires multidisciplinary collaborative management. The clinical data of the 13 patients in this group indicate that lung cancer complicated by NTM infection predominantly occurs in male patients with adenocarcinoma who do not smoke; MAC and Mycobacterium abscessus are the most common NTM species; no obvious worsening of NTM-PD was observed during concurrent treatment in this small retrospective series. The impact of NTM infection on the timing of surgery for early-stage lung cancer warrants clinical attention. Larger-sample prospective studies are needed in the future to clarify the true impact of NTM infection on the prognosis of patients with lung cancer and to optimize comprehensive treatment strategies for these patients. Supplementary The article’s supplementary files as